Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Orlistat is an obesity treatment drug that does not act on the central nervous system. It only acts on the gastrointestinal tract. By inhibiting lipase in the gastrointestinal tract, it prevents the hydrolysis of triacylglycerol into free fatty acids and monoacylglycerides, reduces the absorption of dietary fat (triacylglycerol) by the intestinal mucosa, and promotes the elimination of fat from the body. . Lipase is an enzyme necessary for the decomposition of fat in the gastrointestinal tract. This product can combine with the serine residues of gastric and pancreatic lipase to inactivate lipase, making it unable to decompose fat in food into free fatty acids and inhibiting fat metabolism. Utilization and absorption, in addition, this product can reduce the risk factors associated with obesity.